JP3270000007 (JP3270000007)

$847.5B
Market Cap
37.9
P/E Ratio
0.82
Beta
1.45%
Dividend Yield
Piotroski 7/9Altman Z 4.3 SafeROIC−WACC -3.4%

Quantitative Summary

Deterministic

Financial health metrics are strong: Piotroski 7/9, Altman Z 4.3 (above 3.0 safe zone threshold).

Generated deterministically from quant metrics and financial statements. Not a recommendation.

Algorithmic Teardown

AI-Generated

The capital allocation efficiency presents a structural constraint, as the return on invested capital of 6.3% falls significantly below the weighted average cost of capital at 9.7%, resulting in a negative spread that erodes intrinsic value over time despite a Piotroski F-Score of 7/9 indicating strong fundamental health and an Altman Z-Score of 4.3 suggesting low bankruptcy risk. This valuation disconnect is further illuminated by the DuPont decomposition, where robust gross margins at 36.2% contrast sharply with net margins compressed to just 5.0%, implying that operating leverage or elevated tax/interest burdens are dampening bottom-line returns relative to top-line performance. While revenue growth remains modest at 6.2% year-over-year, the quality of earnings appears bifurcated between high-margin generation and inefficient capital deployment.

Valuation metrics reflect a significant premium to historical norms, with the current price-to-earnings ratio standing at 37.9x, which suggests the market is pricing in substantial future growth that has not yet been realized given the subdued revenue trajectory. However, this aggressive multiple stands in stark contrast to the discounted cash flow model's fair value estimate of $13,677, indicating a wide valuation gap where current market prices may be detached from fundamental cash generation capabilities if implied growth assumptions are not met. The divergence between the high P/E and the DCF-derived floor highlights potential overvaluation unless the company can demonstrably improve its ROIC-WACC spread or accelerate margin expansion to justify the premium multiple.

No specific risk factor deltas, insider trading activity, or Fama-French alpha data were provided in the input; therefore, a synthesis of those specific dimensions is not possible based on the available information. The analysis remains anchored strictly on the observed inefficiency between capital returns and costs, coupled with the tension between elevated market multiples and conservative cash flow valuations.

Generated by LLM from quantitative data inputs. May contain inaccuracies. Not investment advice.

DCF Sandbox

Interactive

Sensitivity Matrix

TG ↓ / WACC →7.7%9.7%11.7%
2%$13615$9893$7719
3%$16094$11089$8399
4%$19912$12705$9257

Center = base case. Green = >10% upside, Red = >10% downside vs .

Pre-computed DCF: WACC=9.7%, terminal growth 3%. Fair value $11089 (+0.0%). Not investment advice.

Price Chart with Moving Averages

Loading chart...
SMA 50 SMA 200

Quant Health Deep Dive

7/9
Piotroski F-Score
Strong — high operational efficiency and profitability signals
4.3
Altman Z-Score
Safe Zone — above 3.0 threshold per academic model. Thresholds: >3 safe, 1.8–3 grey, <1.8 distress.

Profitability & Value Creation

36.2%
Gross Margin
5.0%
Net Margin
6.3%
ROIC
9.7%
WACC
ROIC − WACC Spread: -3.4%— Negative spread.
+6.3%
Revenue Growth (YoY)
-30.4%
Earnings Growth (YoY)
34.1B
Free Cash Flow
29%
FCF Payout Ratio

✅ Conservative payout — room for dividend increases.

Balance Sheet Health

0.62x
Debt / Equity
1.67x
Current Ratio
26.7x
Interest Coverage
-0.3x
Net Debt / EBITDA
4.15%
FCF Yield
87.8B
EBITDA

Earnings Surprise History

Q4
✗ Miss
Est: $89.97
Act: $-34.89
-138.8%
Q3
✗ Miss
Est: $52.88
Act: $50.84
-3.9%
Q2
✓ Beat
Est: $85.34
Act: $105.06
+23.1%
Q1
✗ Miss
Est: $103.13
Act: $93.42
-9.4%

EPS estimates vs actuals for the most recent reported quarters. Source: yfinance.

Underwater (Drawdown from Peak)

How far below the all-time high the price has been over time. Deeper = more pain for holders.

Loading drawdown chart...

Rolling 60-Day Beta vs S&P 500 (VOO)

How the stock's sensitivity to market moves changes over time. β > 1 = more volatile than the market.

Loading beta chart...
Rolling Beta Market (β = 1.0)

Fundamentals

23.1
Forward P/E
PEG Ratio
2.42
Price/Book
489112
Avg Volume
$8882.00
52W High
$3701.00
52W Low
52W Range Position

Passive Flow Attribution

ETF Draft Effect
$52M
Tracked Passive Exposure
3
ETFs Holding JP3270000007
0.02%
Avg Weight in ETFs
$278B
Total ETF AUM

When investors buy or sell ETFs like IEFA or SCHF, the fund manager is mechanically forced to buy or sell JP3270000007 shares regardless of JP3270000007's individual fundamentals. We estimate $52M of passive capital is structurally linked to JP3270000007 through 3 tracked ETFs. Passive flows have a limited but growing influence on JP3270000007's daily trading dynamics.

Passive exposure = Σ (ETF AUM × stock weight in ETF) across 3 tracked ETFs. Actual passive ownership is larger (includes mutual funds). Not investment advice.

ETF Contagion Visualizer

Simulate a price drop in JP3270000007 to visualize passive redemption contagion across ETFs and collateral stocks.

JP3270000007 Shock
-0%
Est. Passive Redemption
$0
Systemic Risk
STABLE
JP3270000007EpicenterIEFAETFSCHFETFIXUSETFNL0010273215Low RiskTW0002330008Low RiskCH0012032048Low RiskCH0012005267Low RiskKR7005930003Low Risk
JP3270000007 Price Drop (%)0

If JP3270000007 (JP3270000007) experiences a significant drawdown, ETF redemptions can create collateral selling pressure on co-held stocks. Our model identifies ASML Holding N.V. (NL0010273215) as the most exposed collateral stock, sharing 2 ETFs with JP3270000007. This is the "Passive Contagion" effect described in the Inelastic Market Hypothesis.

Contagion model based on shared ETF exposure and constituent weights across 3 tracked ETFs. Estimated selling pressure is a simplified model — actual impact depends on market liquidity, ETF redemption mechanics, and market-maker activity.

JP3270000007 Ownership Dynamics

Ticker
JP3270000007

Float lock-up computed from 3 ETFs tracked by SecuritiesDB. Actual passive ownership is higher (includes mutual funds, pension funds, etc.).

JP3270000007 Capital Efficiency

How efficiently does JP3270000007 convert operating profits into free cash? The FCF Conversion ratio measures the gap between accounting earnings and real cash generation.

Free Cash Flow
$34.1B
EBITDA
$87.8B
FCF Conversion
39%
Reinvestment Rate
61%
39% of EBITDA → Free Cash
0% (cash burn)25% (low)50% (efficient)100% (pure cash)
ROIC
6.3%
ROIC − WACC Spread
-3.4%

JP3270000007 converts 39% of its EBITDA into free cash flow, a moderate conversion rate — significant EBITDA is consumed by capital expenditures, working capital changes, or interest payments. The 61% reinvestment rate signals aggressive capacity expansion. However, the ROIC-WACC spread is negative (-3.4%), suggesting reinvested capital is destroying shareholder value.

Capital efficiency = Free Cash Flow ÷ EBITDA. Reinvestment = (EBITDA − FCF) ÷ EBITDA. Metrics from latest annual filings. Not investment advice.

Compare JP3270000007 to Peers

Quant metrics computed deterministically from financial statements and price data. Updated: N/A.

SecuritiesDB provides programmatic data aggregation for informational purposes only. None of the metrics, summaries, or algorithmic flags constitute a recommendation to buy or sell any security.